TP53 and B-cell chronic lymphocytic leukemia: Therefore, the objective of this study was to evaluate the cost-effectiveness of first-line treatment with IB compared with BE plus RI for previously untreated Chinese patients with CLL aged 65 years or older without del(17p)/TP53 mutation using local data.